Clinical Trial Update: Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 first-in-human study of oral TP-1287 in patients with advanced solid tumors, including specific sarcoma subtypes, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dedifferentiated Liposarcoma
• Ewing Sarcoma
• Sarcoma
• Solid Tumors
• Synovial Sarcoma

Drugs mentioned

• TP-1287

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Advanced Solid Tumors, Sarcoma | Phase 1 | Status: TERMINATED